New Option Soon for Some European Patients With Leukemia New Option Soon for Some European Patients With Leukemia


Gilteritinib has been recommended for approval for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation.International Approvals

Related Links:

Contributors : Jacek Marzec ; Jun Wang ; Marwa Saied ; Bryan D Young ; Silvana DebernardiSeries Type : Expression profiling by arrayOrganism : Homo sapiensThe aim was to analyze the expression of genes in cytogenetically distinct cases of AML.

Source: GEO: Gene Expression OmnibusCategory: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research

In conclusion, the anti-leukemic activity of ATG, particularly CDC, is more potent for ALL than AML in vitro. If this applies in vivo, ATG-based GVHD prophylaxis may be particularly advantageous for ALL.

Source: CytotherapyCategory: Cytology Source Type: research

In this study, the protein–ligand interactions between FLT3 kinase domain (wild-type or F691L) and quizartinib or PLX3397 were compared via an integrated computational approach. The classical molecular dynamics (MD) simulations in conjunction with dynamic cross-correlation (DCC) analysis, solvent-accessible surface area (SASA), and free energy calculations indicated that the resistant mutation may induce the conformational change of αC-helix and A-loop of the FLT3 protein. The major variations were controlled by the electrostatic interaction and SASA, which were allosterically regulated by residues Glu-661 and …

Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Rafiye Ciftciler, Haluk Demiroglu, Ibrahim Celalettin Haznedaroglu, Nilgun Sayınalp, Salih Aksu, Osman Ozcebe, Hakan Goker, Muruvvet Seda Aydın, Yahya BuyukasıkAbstractBackgroundThe majority of patients with acute myeloid leukemia (AML) receive intensive induction chemotherapy for obtaining a complete remission (CR). Despite consolidation chemotherapy and advances in allogeneic hematopoietic stem cell transplantation, most of these patients finally relapse and die from AML. The aim of this study is to determine the …

Bone Marrow Transplantation, Published online: 19 September 2019; doi:10.1038/s41409-019-0689-8Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis

Source: Bone Marrow TransplantationCategory: Hematology Authors: Source Type: research

In conclusion, AuSCT may still have a role in FR and IR MRD-negative categories. In the IR MRD-positive category, AlloSCT prolongs OS and DFS to equal those of the FR category. Using all the available sources of stem cells, AlloSCT was delivered to 71% of the candidates.This trial was registered at as #NCT01452646 and EudraCT as #2010-023809-36.

Source: BloodCategory: Hematology Authors: Tags: Myeloid Neoplasia, Clinical Trials and Observations Source Type: research

By combining the analysis of mutations with aberrant expression of genes previously related to poorer prognosis in both acute promyelocytic leukemia (APL) and acute myeloid leukemia, we arrived at an integrative score in APL (ISAPL) and demonstrated its relationship with clinical outcomes of patients treated with all-trans retinoic acid (ATRA) in combination with anthracycline-based chemotherapy. Based on fms-like tyrosine kinase-3–internal tandem duplication mutational status; the Np73/TAp73 expression ratio; and ID1, BAALC, ERG, and KMT2E gene expression levels, we modeled ISAPL in 159 patients (median ISAPL score,…

Source: BloodCategory: Hematology Authors: Tags: Myeloid Neoplasia Source Type: research

BioTheryX plans to continue building out Board of Directors with key biopharma industry leaders as Company transitions from preclinical to clinical stage with lead Acute Myeloid Leukemia (“AML”) compound BTX-A51

CHAPPAQUA, N.Y., Sept. 18, 2019… Biopharmaceuticals, Oncology, Personnel BioTheryX, Protein Homeostatic Modulators

Source: HSMN NewsFeedCategory: Pharmaceuticals Source Type: news

Condition:   Acute Myeloid Leukemia Interventions:   Drug: Gemtuzumab Ozogamicin 147;   Drug: Gemtuzumab Ozogamicin 1;   Drug: Glasdegib;   Drug: Placebo Oral Tablet Sponsor:   University Hospital Heidelberg Not yet recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Source link